INTRODUCTION AND OBJECTIVES:
There remains a perception that cystectomy following prior pelvic irradiation (PPI) confers worse outcomes. With the increasing experience in robot assisted cystectomy (RAC), we report the feasibility and peri-operative outcomes of patients undergoing post-pelvic irradiation robot-assisted cystectomy (P-PIRAC) compared to RAC in patients without PPI.
METHODS: We performed a prospective single-centre review of 529 patients treated with cystectomy from January 2009 to June 2018. 316 patients underwent RAC, of which 25 (7.9%) received PPI (Group A). This was compared with to 291 patients who did not receive PPI (Group B). Co-morbidities were quantified using the Charlson co-morbidity index (CCI), and peri-operative complications were recorded in each group. RESULTS: Patients in Group A were older (mean age 72 vs 68 years, p [ 0.028) but fitter (ASA Score 3: 4% vs 16%, p[0.012). Whilst there was no statistically significant difference in baseline demographics (gender, race, body mass index), a greater number of patients in Group A received chemotherapy (44% vs 15%, p < 0.001).
There was no differences in short and median term perioperative outcomes between the two groups (Table 1) , and on multivariate analysis, only increasing age (OR 1.04, 95% CI 1.01 -1.07, p [ 0.017) and longer operative time (OR 1.005, 95% CI 1.001 -1.009, p [ 0.012) were associated a higher 90-day complication rate. PPI was not associated with an increased intra-operative (OR 0.62, 95% CI 0.13 -2.86, p [ 0.539) or 90-day complication rate (OR 0.82, 95% CI 0.25 -2.68, p [ 0.740) ( Table 2) .
CONCLUSIONS: P-PIRAC should be standard of care in high volume RAC units. It provides durable short and medium term outcomes and is a safe option with complication rates not dissimilar to RAC in patients without PPI. T2 to non-organ confined pathologic stage !T3 or Nþ at radical cystectomy (RC) is common and can significantly increase the risk of cancerspecific mortality (CSM). We assessed the ability of a genomic subtyping classifier (GSC) to predict pathological upstaging in a multi-institutional cohort of patients with clinical T1-T2 bladder cancer treated with RC.
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MP26-15 MOLECULAR SUBTYPING REVEALS LUMINAL BLADDER TUMORS HAVE LOWER RATES OF PATHOLOGICAL UPSTAGING
METHODS: A cohort of 206 patients with clinical high-grade, organ-confined (cT1-T2, N0M0) treated with RC and bilateral PLND without neoadjuvant chemotherapy (NAC) was selected from the registries of 7 academic hospitals. Precystectomy bladder tumor transurethral resection FFPE specimens were submitted for
